MedTrace Logo

Bevacizumab + Paclitaxel + Capecitabine in Triple Negative Metastatic Breast Cancer

NCT01069796 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2016-03-17

No results posted yet for this study

Summary

Patients with triple negative metastatic breast cancer (HER2-, PR-, ER-) will receive bevacizumab, paclitaxel and capecitabine as a first line of treatment (possibility to have received adjuvant chemotherapy).

Conditions

  • Triple Negative Metastatic Breast Cancer

Interventions

DRUG

Paclitaxel

80 mg/m² weekly

DRUG

Bevacizumab

10 mg/kg d1 d15

DRUG

Capecitabine

800 mg/m² p.o. twice a day, D1 to D5 week 1, 2 \& 3

Sponsors & Collaborators

  • ARCAGY/ GINECO GROUP

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2012-03-31
Completion
2014-06-30

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01069796 on ClinicalTrials.gov